4 stories mentioning SHA:600535Updated 4d ago
Every FINWIRES story that references SHA:600535, newest first.
China's drug regulator approved the bosentan dispersible drugs produced by Tasly Pharmaceutical (SHA:600535) subsidiary Jiangsu Tasly DiYi Pharmaceutical, according to a Tuesday filing with the Shanghai bourse.The drug is indicated for pulmonary arterial hypertension.
China's drug regulator approved Tasly Pharmaceutical's (SHA:600535) Zao Ren Ning Xin Di Wan traditional medicine.The drops help with insomnia due to heart and liver deficiencies, according to a Tuesday bourse filing in Shanghai.
China's drug regulator approved Tasly Pharmaceutical (SHA:600535) subsidiary Jiangsu Tasly DiYi Pharmaceutical's vonoprazan fumarate tablets, according to a Saturday filing with the Shanghai bourse.The drug is indicated for reflux esophagitis, or the inflammation of the esophageal lining due to acid reflux. It is used combination with antibiotics against helicobacter pylori, the pharmaceutical company said.
Tasly Pharmaceutical (SHA:600535) posted net profit attributable to shareholders of 370.2 million yuan for the first quarter of 2026, up 18% from 314.3 million yuan a year earlier, according to an April 24 filing on the Shanghai Stock Exchange.Earnings per share came in at 0.2478 yuan, compared with 0.2104 yuan in the prior-year period.Revenue rose 5.4% year on year to 2.16 billion yuan from 2.05 billion yuan.Tasly's shares rose nearly 3% in recent trade.
